News | July 14, 2009

Study Looks at Long-term Outcomes of DES Use in Patients With RI

July 14, 2009 – Despite the fact that drug-eluting stent (DES) implantation reduces restenosis and the need for target vessel revascularization (TVR), these stents appear to be associated with unfavorable long-term outcomes in patients with moderate or severe renal insufficiency (RI), according to a study in this week’s issue of the International Journal of Cardiology, Volume 136, Issue 1, pages 72-79, July 2009.

Researchers at Rui Jin Hospital and Jiao Tong University School of Medicine in Shanghai, China, sought to examine the impact of moderate or severe RI on long-term clinical outcomes after successful percutaneous coronary intervention (PCI) with drug-eluting stent implantation. They found all-cause mortality and major adverse cardiac events were prospectively determined for 1,174 patients after successful PCI with drug-eluting stent implantation. Based on estimated creatinine clearance (CrCl) levels, long-term outcomes were compared between patients with CrCl

Patients in the RI group were older, mainly female and had lower body weights and hemoglobin than those in the control group. The RI group also had fewer cigarette smokers. During follow-up (averaged 19.2 months) after successful PCI, all-cause death (8.3 percent vs. 1.5 percent), cardiac death (5.7 percent vs. 1.1 percent) and occurrence of nonfatal myocardial infarction (2.2 percent vs. 0.4 percent) were significantly higher, but the rate of TVR was lower (5.7 percent vs. 9.6 percent) in the RI group than in the control group. Multivariate analysis revealed that a CrCl

For more information: www.internationaljournalofcardiology.com


Related Content

News | Stents

April 17, 2024 — Getinge and Cook Medical announced an exclusive sales and distribution agreement for the iCast covered ...

Home April 17, 2024
Home
News | Stents

March 8, 2024 — Silk Road Medical, Inc., a company focused on reducing the risk of stroke and its devastating impact ...

Home March 08, 2024
Home
News | Stents

January 19, 2024 — W. L. Gore & Associates, Inc. announced that the first patients have been enrolled in the Gore VBX ...

Home January 19, 2024
Home
News | Stents

November 29, 2023 — InspireMD, Inc., developer of the CGuard Embolic Prevention Stent System (EPS) for the prevention of ...

Home November 29, 2023
Home
News | Stents

July 27, 2023 — Abiomed is recalling the Impella Intravascular Left Sided Blood Pumps because the pump’s Instructions ...

Home July 27, 2023
Home
News | Stents

June 13, 2023 — W. L. Gore & Associates (Gore) announced the initiation of the Gore VBX FORWARD Clinical Study ...

Home June 13, 2023
Home
News | Stents

March 5, 2023 — In patients with multi-vessel heart disease who have had a heart attack, immediate treatment with stents ...

Home March 05, 2023
Home
News | Stents

January 23, 2023 — A study of more than 100,000 patients has revealed that, for patients with blockages in multiple ...

Home January 23, 2023
Home
News | Stents

July 5, 2022 — A BIO-RESORT subgroup analysis of outcomes in small coronary vessels (<2,5mm) evaluated the efficacy and ...

Home July 05, 2022
Home
News | Stents

June 2, 2022 — According to the U.S. Food and Drug Administration (FDA), Atrium Medical Corporation is recalling the ...

Home June 02, 2022
Home
Subscribe Now